Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be participating in Oppenheimer's 34th Annual Healthcare Life Sciences Conference and BTIG at Snowbird on February 13-14, 2024.

Simulations Plus to Participate in Upcoming Healthcare Conferences

Simulations Plus (SLP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -5.35% in 4 Weeks, Here's Why You Should You Buy the Dip in Simulations Plus (SLP)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of GastroPlus version 9.9 with key enhancements from FDA collaborations, client feedback, and current research.

Simulations Plus Releases GastroPlus® Version 9.9

Simulations Plus (SLP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Simulations Plus (SLP), Here's Why It's a 'Buy' Now

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new FDA-funded collaboration with Northeastern University and The TIM Company to develop modified-release drug products.

Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant

Simulations Plus' (SLP) first-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments amid relatively soft client funding and budget cycles.

Simulations Plus (SLP) Q1 Earnings Miss, Revenues Rise Y/Y

Simulations Plus, Inc. (SLP) Q1 2024 Earnings Call Transcript

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 1st quarter of fiscal year 2024; details will be discussed in a conference call at 5pm ET.

Simulations Plus Reports First Quarter Fiscal 2024 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced several key leadership appointments and promotions today, including the addition of Dan Szot as Chief Revenue Officer.

Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth

Simulations Plus (SLP) fiscal first-quarter performance is likely to have benefited from momentum across Software and Services business segments.

Simulations Plus (SLP) to Report Q1 Earnings: What's in Store?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse.

Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.

Simulations Plus Outlines Paths to Win at 2023 Investor Day

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, and the leadership team will participate in the Company's virtual Investor Day on Tuesday, Nov 14, at 1 p.m. ET.

Simulations Plus to Host Investor Day on Tuesday, November 14th

Simulations Plus, Inc. (NASDAQ:SLP ) Q4 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum David Larsen - BTIG David Windley - Jefferies Operator Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q4 2023 Earnings Call Transcript

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter and full fiscal year 2023. Total FY23 revenue increased 11% to $59.6 million.

Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 25, 2023, at 5pm ET to discuss 4th quarter & fiscal year 2023 financial results.

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.

Simulations Plus Receives New FDA Grant Award

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.

Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors

LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.

Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

LANCASTER, Calif.--(BUSINESS WIRE)--The July 2023 issue of Clinical Pharmacology & Therapeutics published research where DILIsym was used to predict liver safety of CBD & VPA treatments.

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of ADMET Predictor 11 with significant enhancements expressly designed to accelerate drug discovery research.

Simulations Plus Releases ADMET Predictor® 11

Simulations Plus' (SLP) third-quarter fiscal 2023 top line is driven by higher revenues in the Software and Services business segments.

Simulations Plus (SLP) Q3 Earnings Miss, Revenues Rise Y/Y

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET Company Participants John Wilfong - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum David Larsen - BTIG Yuan Zhi - B. Riley Francois Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2023 Financial Results Conference Call.

Simulations Plus, Inc. (SLP) Q3 2023 Earnings Call Transcript

Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.20 per share a year ago.

Simulations Plus (SLP) Q3 Earnings Miss Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported revenue growth in the 3rd quarter of FY23 with 3Q revenue up 9% to $16.2 million; 9mo revenue up 4% to $43.9 million.

News for Simulations Plus Stock (SLP)